Equillium (NASDAQ:EQ) Trading 1% Higher

Shares of Equillium, Inc. (NASDAQ:EQ – Get Rating) traded up 1% during trading on Tuesday . The company traded as high as $1.05 and last traded at $1.02. 42,255 shares were traded during trading, a decline of 49% from the average session volume of 82,164 shares. The stock had previously closed at $1.01.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price target on Equillium from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, September 27th.

Equillium Stock Performance

The stock has a market cap of $35.10 million, a P/E ratio of -0.44 and a beta of 1.23. The company has a fifty day moving average price of $1.30 and a 200 day moving average price of $1.89. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.13 and a quick ratio of 3.13.

Equillium (NASDAQ:EQ – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01). On average, equities analysts expect that Equillium, Inc. will post -1.55 EPS for the current year.

Institutional Investors Weigh In On Equillium

Institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in shares of Equillium by 13.2% during the 1st quarter. State Street Corp now owns 56,220 shares of the company’s stock valued at $177,000 after purchasing an additional 6,564 shares during the last quarter. Jane Street Group LLC bought a new position in Equillium during the 1st quarter worth approximately $47,000. Dimensional Fund Advisors LP bought a new position in Equillium during the 3rd quarter worth approximately $43,000. Renaissance Technologies LLC bought a new position in Equillium during the 2nd quarter worth approximately $34,000. Finally, Capital CS Group LLC bought a new position in Equillium during the 4th quarter worth approximately $25,000. Institutional investors own 37.64% of the company’s stock.

Equillium Company Profile

(Get Rating)

Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.